Corporate Banner
Satellite Banner
Informatics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Genedata Biologics 4.0 Enables Large-scale Design, Synthesis, and Testing of Bispecific Antibodies

Published: Wednesday, April 02, 2014
Last Updated: Tuesday, April 01, 2014
Bookmark and Share
Integrated biologics data workflow system now supports fully automated, high-throughput next-generation antibody generation and characterization

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, has announced the release of Genedata Biologics™ 4.0, the latest version of its enterprise workflow support and data management solution for biologics R&D. This major new release provides novel tools for systematically designing, cloning, expressing, purifying, and testing bi- and multi-specific antibodies. Able to simultaneously co-engage with different antigen targets, these new antibody formats are currently being broadly adopted by the biopharmaceutical industry, primarily for developing the next-generation of oncology and immune system therapies. Genedata Biologics is meeting the challenges of developing these complex multi-specific antibodies by providing new tools to enable more efficient molecule design, production, and characterization.

High-Throughput Next-Generation Antibody Generation and Testing

Genedata Biologics 4.0 enables standardized processing and assessment of next-generation antibody formats (e.g. Fab-scFv, KinH, IgG-scFv, DVD-Ig, tandem-scFv-Fc), including the huge underlying combinatorial complexity of all parametric variants (e.g. linkers, V-domain order, Fc). In addition to supporting established formats, the system can be configured to work with completely novel multi-specific antibody-like molecules, new scaffolds, and proprietary engineering techniques (e.g. Fc-engineering, chimerization, humanization). Automating downstream expression, purification, and characterization processes, Genedata Biologics substantially increases throughput.

Genedata Biologics resolves major bottlenecks in high-throughput molecular biology and cloning processes. These processes are required to systematically generate and validate DNA constructs to express the desired next-generation molecules. The platform supports multi-specific engineering strategies by identifying the most successful combination of antigen binders and formats and scales up cloning and production by directly integrating with laboratory automation equipment. Genedata Biologics also automatically aggregates all assay and analytics results, facilitating decision-making on which candidate to move forward.  

"The next-generation of biotherapeutics are built on bispecifics and other innovative, highly engineered large-molecules such as antibody drug conjugates. Therefore, today's biopharmas are faced with generating and testing vastly increased numbers of diverse alternative antibody molecule formats," said Dr. Othmar Pfannes, CEO of Genedata. "This new version of Genedata Biologics can handle increasingly complex and proprietary molecule types and enables the necessary throughput and automation to get new high-quality candidates into clinical development faster. This makes Genedata Biologics the workflow management platform of choice for all biologics R&D organizations."

Genedata Biologics V 4.0 is available now and shipping directly from Genedata.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Boehringer Ingelheim Chooses Genedata Selector for Cell Line Development and Cell Culture Optimization
Company has announced that the leading pharma company to implement Genedata Selector as its global cell line and genome knowledge management platform.
Thursday, March 10, 2016
Genedata Signs License Agreement with AstraZeneca
Genedata Screener now AstraZeneca’s corporate platform for expediting drug discovery.
Saturday, November 21, 2015
Kymab Implements Genedata Biologics for High-throughput Antibody Discovery
Genedata Biologics™ integrated workflow platform used to increase throughput and automation of Kymab’s transgenic mice-based discovery platforms.
Tuesday, November 17, 2015
Genedata Completes Important Milestone in Collaboration with Bayer Pharma AG
Successful integration of Genedata Profiler™ allows researchers to access, process, analyze and manage petabytes of NGS and other omics data from patients and pre-clinical experiments.
Thursday, September 24, 2015
Merck Serono Chooses Genedata Biologics to Streamline Antibody Discovery Processes
Global deployment of Genedata Biologics across multiple protein therapeutics R&D groups to standardize workflows and improve efficiency.
Thursday, July 23, 2015
Genedata Releases a Breakthrough for Genomic Comparison
Genedata Selector™4.0 provides reference-independent genome sequence comparisons while reducing data processing and analysis time to optimize efficiency and save costs.
Wednesday, July 22, 2015
Genedata Forges Alliance with Intellicyt
Swiss informatics firm Genedata and Intellicyt today announced an alliance to work on cell-based screening in drug discovery.
Thursday, June 18, 2015
Precision Medicine Software Genedata Profiler™ Launched at Bio-IT World
Open, interoperable enterprise platform for patient and compound profiling provides important data management infrastructure for pharma internal R&D processes.
Friday, April 24, 2015
Partner on Innovative Workflow Platform for High-Throughput Cell Line Development
Novel Cell Line Development (CLD) data platform to support the generation and assessment of mammalian production cell lines.
Tuesday, March 17, 2015
Genedata, Bayer Pharma AG Partner on Innovative Workflow Platform for High-Throughput Cell Line Development
Novel Cell Line Development (CLD) data platform to support the generation and assessment of mammalian production cell lines.
Tuesday, March 17, 2015
Genedata Biologics Licensed by Pfizer
Pfizer implements Genedata Biologics to streamline global biopharma R&D processes.
Wednesday, March 04, 2015
Boehringer Ingelheim Selects Genedata Biologics as Antibody Discovery Workflow Platform
Genedata Biologics integrates and streamlines workflows for protein therapeutics R&D groups across multiple Boehringer Ingelheim sites.
Thursday, February 19, 2015
Exploring Innovations in SPR & Combination Screening
Genedata customers will discuss innovations in high content imaging, high throughput screening, compound combination screening, and other related topics at User Group Meetings.
Tuesday, August 26, 2014
GSK Implements Genedata Biologics as Antibody Discovery Platform
Genedata Biologics integrates GlaxoSmithKline's Biopharm Discovery workflows across multiple Biopharm R&D groups and sites
Thursday, June 12, 2014
Genedata Showcases Integrated Analysis & Image Management Solution for Phenotypic Screening
Regardless of instrument or application, Genedata Screener® for High Content Screening enables time-efficient workflow for analysis of high-content experiments
Friday, February 21, 2014
Scientific News
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
‘Precision Prevention’ for Colorectal Cancer
New risk prediction model — not yet ready for clinical use — incorporates genetic, lifestyle and environmental risk factors.
Characterizing Cancerous Genomic Variations
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Uncovering Hidden Genomic Alterations that Drive Cancers
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Spotting DNA Repair Genes Gone Awry
Ludwig researchers develop a two-pronged approach for identifying genes responsible for fixing DNA damage that can trigger cancer when compromised.
Interpreting “Dark Matter” DNA
Scientists at the Gladstone Institutes have invented a new way to read and interpret the human genome.
A Programming Language for Living Cells
New language lets researchers design novel biological circuits.
The Epigenetics of Childhood Cancer
Qlucore software enables researchers to more easily study the genetic influences behind childhood cancer.
Mining Whole Exome Data to Improve Cancer Therapies
New tool interprets the raw data of whole exome tumor sequencing and then matches the cancer’s unique genetics to FDA-approved targeted treatments.
Pittcon 2016: Accelerating Innovation And Enhancing Productivity With Technology
Collaboration and externalization of data highlight evolving lab operations.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!